Science & Medicine

TSR Special Report – Sanofi



(In advance of tomorrow’s publication of the ASH issue of MPNforum)

Special report on Sanofi from TSR:

A month ago, Sanofi abruptly terminated its JAK inhibitor clinical trial leaving patients on short notice without options.  Sanofi won’t give details. The FDA won’t tell us because of regs, FOIA rejected us based on trade secrets. So MPNforum investigated and found another 180 million reasons for Sanofi to dump us from its Fedratinib Phase III clinical trial.

  Available now at:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: